Sun Pharmaceutical launches Winlevi cream in US market

01 Nov 2021 Evaluate

Sun Pharmaceutical Industries has launched Winlevi cream in US market. Winlevi cream used for the treatment of acne vulgaris in patients 12 years and older. A first-in-class topical androgen receptor inhibitor, Winlevi was approved by the US Food and Drug Administration (USFDA) in August 2020. Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years.

The US launch of Winlevi enhances Sun Pharma's specialty product portfolio and reflects commitment to meeting patients needs by providing innovative dermatology medicines.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1639.30 7.65 (0.47%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×